Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Process Upgrade Recombivax HB in Healthy Young Adults
NCT00489099Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- May 2006
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
01
Overview
A Phase 3 trial of hepatitis B vaccine (recombinant) in hepatitis B (HBV), sponsored by Merck & Co.. Started Jun 2005; status: completed.
02
Drugs
hepatitis B vaccine (recombinant)
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00489099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00489099.